FDA strengthens valproate pregnancy restrictions: mandatory REMS enrolment and enhanced counselling requirements

FDA has revised the Valproate REMS programme — which applies to all sodium valproate, valproic acid, and divalproex sodium products (Depakote, Depakene, Depacon, and generics) — to add new mandatory requirements for female patients of childbearing potential. Key changes: (1) Patient enrolment: all female patients aged 2–55 years must be enrolled in the REMS before the first prescription and at each annual renewal; (2) Annual counselling attestation: prescribers must document that the patient has been counselled on teratogenicity, fetal valproate syndrome risk, and effective contraception; (3) Consumer Medication Guide: updated CMG with structured risk discussion must be dispensed with every prescription; (4) Pharmacist dispensing obligations: pharmacists must verify REMS enrolment status before dispensing. The FDA REMS database ↗ lists all enrolled prescribers. See the pregnancy and drugs guide.

Valproate is classified as FDA Pregnancy Category X / FDAAA high-risk teratogen. The key risks: (1) Neural tube defects: risk approximately 1–2% (vs 0.06–0.07% background) — open spina bifida and anencephaly; highest risk in first trimester; (2) Major congenital malformations: overall rate ~10% in exposed pregnancies — craniofacial (cleft lip/palate), cardiac septal defects, hypospadias, limb defects; (3) Fetal valproate syndrome: a recognisable pattern of minor dysmorphic features including broad nasal bridge, small nose, metopic ridging; (4) Neurodevelopmental effects: most concerning for long-term outcomes — in utero exposure associated with IQ 7–10 points below matched controls (NEAD study), higher rates of autism spectrum disorder (~5-fold), ADHD, and language delay; (5) Neonatal effects: neonatal valproate syndrome (jitteriness, feeding difficulties, liver toxicity), neonatal withdrawal. Valproate should not be used for migraine prophylaxis in women of childbearing potential, and is generally avoided for epilepsy when safer alternatives exist. See neonatal pharmacology guide.

For patients with epilepsy or bipolar disorder who require valproate, the clinical framework is: (1) Contraception counselling: effective contraception (LARC preferred — intrauterine device, subdermal implant) must be used while on valproate; note valproate may reduce levonorgestrel efficacy via CYP induction — combined hormonal contraception or LARC preferred; (2) Folic acid supplementation: 5 mg/day folic acid (higher dose than standard) started at least one month pre-conception if pregnancy is considered; some authorities recommend 5 mg folic acid for all women of childbearing potential on valproate; (3) If pregnancy occurs: do not abruptly discontinue — sudden valproate cessation risks status epilepticus; seek immediate specialist review; antenatal detailed anatomical ultrasound and fetal echocardiography; (4) TDM in pregnancy: valproate unbound clearance increases substantially in pregnancy (increased renal clearance, altered protein binding) — monitoring free valproate levels (not total) essential. See TDM guide and NTI drug management.

For epilepsy: lamotrigine, levetiracetam, and carbamazepine have lower teratogenicity than valproate, though all AEDs carry some risk; lamotrigine is preferred in women of childbearing potential for focal epilepsy; for absence epilepsy (where valproate has highest efficacy), ethosuximide is an alternative for isolated absence seizures. For bipolar disorder: quetiapine and lamotrigine are preferred mood stabilisers; lithium has a lower but real teratogenic risk (Ebstein anomaly) and requires very different risk counselling; note that untreated bipolar disorder itself carries fetal and maternal risks. For migraine prophylaxis: valproate is absolutely contraindicated — topiramate (also teratogenic), propranolol, amitriptyline, or CGRP antagonist monoclonal antibodies (limited pregnancy data) are alternatives. Links: pregnancy and drugs, pharmacogenomics in practice.